ARK Reports 10.18% Cerus Stake — Its Innovation ETF Has An Interest Above 5%

The September 30 position covers 20,508,004 shares and was jointly reported by ARK and its chief executive.

Share
ARK Reports 10.18% Cerus Stake — Its Innovation ETF Has An Interest Above 5%

ARK Investment Management reported a 10.18% stake in Cerus, which sells systems that reduce pathogens in donated blood, in an SEC ownership filing Friday. The position covers 20,508,004 common shares, with ARK Innovation ETF identified as a client whose interest exceeds 5% in the reported securities.

One Position, Jointly Reported

The holdings were measured on September 30, 2026. Catherine D. Wood, ARK's chief executive officer and chief investment officer, reported the same share count and percentage alongside the investment manager.

ARK and Wood agreed to report jointly. Their matching ownership entries describe the same position, so the shares are not separate holdings to be added together.

ARK had sole authority to vote 19,250,797 shares and shared authority over 237,139 shares. Wood reported shared voting authority over 19,487,936 shares. ARK had sole authority to direct the sale of all 20,508,004 shares; Wood reported shared authority over that amount.

ARK classified the holding as passive, certifying that it held the shares in its normal business activities without a purpose of changing or influencing Cerus's control. Its Innovation ETF was the client exception to its statement that client interests did not exceed 5% of the reported securities.

Cerus's Blood-Safety Business

Cerus develops and sells the INTERCEPT Blood System to blood collection organizations, including the American Red Cross, a key customer. The system is designed to reduce viruses, bacteria and parasites in blood components before transfusion.

Its platelet and plasma systems have FDA approval in the United States and the European Union's CE Mark. Cerus uses its own sales staff and distributors to sell in the United States, parts of Europe, the Commonwealth of Independent States, the Middle East and Latin America.

The company also sells INTERCEPT Fibrinogen Complex, a plasma-derived treatment for bleeding associated with fibrinogen deficiency, and U.S. kits used to produce it. Its red blood cell system remains in clinical trials and has not been sold anywhere.

ARK's concentrated ETF holdings in small and midsize companies frequently cross ownership-reporting thresholds. About 170 ownership schedules over two years place the Cerus position within that recurring pattern.

Cerus had a market value of $392 million as of 1:14 p.m. ET Friday.

Sources

More on Cerus

All Cerus (CERS) coverage →